Jonathan Berlent Joins Merakris as SVP, Head of Strategy and Operations
09 Mayo 2024 - 5:30AM
Merakris Therapeutics announced today that Jonathan Berlent has
joined the company as Senior Vice President, Head of Strategy and
Operations.
Berlent will report to Merakris CEO Chris Broderick and be
responsible for corporate strategy and business operations
including new business development. He will serve as a member of
the company’s Executive Management Committee.
Berlent has spent the last 20 years in executive leadership
roles within the pharmaceutical and life science industries. He
most recently served as President of North American Operations for
Sentiss Pharmaceuticals, a sterile ophthalmic developer,
manufacturer and distributor of U.S Food and Drug Administration
(FDA) approved products. In that role, he spearheaded Sentiss’
strategic growth through R&D driven portfolio initiatives and
global market expansion, including the acquisition of a diverse
portfolio of products and an FDA-approved cGMP sterile
manufacturing facility.
Berlent holds a bachelor’s degree in economics from the
University of Michigan and an MBA from NYU’s Stern School of
Business, where he majored in finance and management.
“Jonathan’s extensive healthcare experience, proven track record
and industry insights are a welcome addition to Merakris’
leadership team,” Broderick said. “In particular, his experience
developing growth strategies will be critically important as we
continue to expand our pipeline and strategic initiatives through
business development. Jonathan’s appointment heightens our focus on
leveraging our platform technologies and cGMP facilities for
expanding our commercial footprint.”
“I’m impressed by the talent at Merakris, and the tremendous
progress the business has made in developing its line of innovative
wound care products in the eight years since it was founded,”
Berlent added. “I look forward to helping drive Merakris’ expansion
efforts and to strengthening its leadership position in wound
healing and tissue regeneration.”
About Merakris
Merakris Therapeutics – founded in 2016 and headquartered in
Research Triangle Park, N.C. – pioneers the use of commercially
scalable stem cell-derived biotherapeutic technologies to promote
the healing of damaged tissue. The company also is investigating
other novel biotechnology solutions that promote wound healing and
tissue regeneration.
Merakris Forward Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates regarding the marketing and other potential of Merakris’
products, or regarding potential future revenues from any such
product. Forward-looking statements are generally identified by the
words "expects", "anticipates", "believes", "intends", "estimates",
"plans" and similar expressions. Although Merakris’ management
believes that any forward-looking statements in this press release
are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond the control of Merakris, that could cause actual results and
developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, unexpected regulatory actions or delays, or government
regulation generally, that could affect the availability or
commercial potential of the product, the fact that product may not
be commercially successful, the uncertainties inherent in research
and development, including future clinical data and analysis of
existing clinical data relating to the product, including post
marketing, unexpected safety, quality or manufacturing issues,
competition in general, risks associated with intellectual property
and any related future litigation and the ultimate outcome of such
litigation, and volatile economic and market conditions may have on
us, our customers, suppliers, vendors, and other business partners,
and the financial condition of any one of them, as well as on our
employees and advisors and on the global economy as a whole.
Bryant HaskinsOtter Creek
Communicationsbryanthaskins@gmail.com(c) 973 590 9537